Expert Insights

Tiffany Traina, MD, discusses the role of immune checkpoint inhibitors in patients with early-stage and metastatic triple-negative breast cancer, highlighting KEYNOTE-522 findings, PD-L1-guided patient selection, limitations of immunotherapy...

Sara Nunnery, MD, discusses advances in oral SERD therapy for HR-positive, HER2-negative metastatic breast cancer, highlighting ESR1 mutation testing, ctDNA guided treatment switching from SERENA-6, emerging endocrine therapy combinations,...

Rebecca Porter, MD, discusses evolving treatment strategies for recurrent ovarian cancer, highlighting the expanding role of antibody-drug conjugates, FRα and HER2-biomarker testing, and the importance of integrating molecular...

Robert Fenstermaker, MD, discusses survival findings with the SurVaxM cancer vaccine in newly diagnosed patients with glioblastoma, highlighting improved long-term survival among younger patients, age-related differences in treatment benefit,...

Seth Wander, MD, PhD, discusses advances in endocrine therapy for ER-positive, HER2-negative metastatic breast cancer, highlighting emerging oral SERDs, ESR1 mutation testing, ctDNA-guided treatment strategies from SERENA-6, and novel...

Vanda Salutari, MD, discusses updated results from the phase 1 BEHOLD-1 trial evaluating the B7-H4-directed antibody-drug conjugate Mo-Rez in platinum-resistant ovarian cancer, highlighting durable antitumor activity, promising...

In the final round, panelists consider frontline treatment selection for an older, functionally independent patient, weighing toxicity profiles, administration approaches, supportive care, and dose modifications against treatment goals and...

The discussion turns to a patient with baseline CNS metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.